Brief: TRACON Pharmaceuticals Inc And Eucure BiopharmaAnnounce Partnership For Development Of Clinical Stage CTLA-4 Antibody YH001

TRACON Pharmaceuticals

11/10/2021 13:12

Oct 11 (Reuters) - TRACON Pharmaceuticals Inc  TCON.O :
    * TRACON PHARMACEUTICALS AND EUCURE BIOPHARMA, A SUBSIDIARY
OF
BIOCYTOGEN, ANNOUNCE PARTNERSHIP FOR DEVELOPMENT OF CLINICAL
STAGE CTLA-4 ANTIBODY YH001
    * TRACON PHARMACEUTICALS INC - INTENDS TO INITIATE A PHASE 1
TRIAL
OF YH001 IN COMBINATION WITH ENVAFOLIMAB IN SOFT TISSUE SARCOMA
    * TRACON PHARMACEUTICALS INC - TO STUDY YH001 IN MULTIPLE
OTHER
SELECTED TUMOR TYPES
    * TRACON PHARMACEUTICALS INC - TRACON WILL BEAR COSTS OF
CLINICAL
TRIALS AND EUCURE BIOPHARMA WILL SUPPLY YH001
    * TRACON PHARMACEUTICALS - GOING FORWARD, INTEND TO USE
YH001
RATHER THAN YERVOY IN OUR FUTURE DUAL CHECKPOINT INHIBITION
TRIALS IN SARCOMA
    * TRACON PHARMACEUTICALS INC - WILL OWE EUCURE BIOPHARMA
ESCALATING DOUBLE DIGIT ROYALTIES ON NET SALES
    * TRACON - WILL BE RESPONSIBLE FOR CLINICAL DEVELOPMENT AND
COMMERCIALIZATION OF YH001 IN MULTIPLE ONCOLOGY INDICATIONS IN
NORTH AMERICA

Source text for Eikon:  ID:nGNX1bNQKt 
Further company coverage:  TCON.O